FDA approves Konvomep for benign gastric ulcers, risk reduction for upper GI bleeding
The FDA has approved an oral suspension omeprazole and sodium bicarbonate for the treatment of active benign gastric ulcer and to reduce risk for upper gastrointestinal bleeding, according to an Azurity Pharmaceuticals press release.With this approval, Konvomep – consisting of 2 mg omeprazole and 84 mg sodium bicarbonate per mL after reconstitution – is indicated as a short-term treatment (40 mg once daily for 4-8 weeks) for adults with benign gastric ulcers. It is also indicated as risk reduction for upper GI bleeding in critically ill adult patients, with an initial dosage of 40Read More
